167 related articles for article (PubMed ID: 10777708)
1. Drug-induced desensitization of insulinotropic actions of sulfonylureas.
Ball AJ; McCluskey JT; Flatt PR; McClenaghan NH
Biochem Biophys Res Commun; 2000 Apr; 271(1):234-9. PubMed ID: 10777708
[TBL] [Abstract][Full Text] [Related]
2. ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 beta-cell line.
Chapman JC; McClenaghan NH; Cosgrove KE; Hashmi MN; Shepherd RM; Giesberts AN; White SJ; Ammälä C; Flatt PR; Dunne MJ
Diabetes; 1999 Dec; 48(12):2349-57. PubMed ID: 10580423
[TBL] [Abstract][Full Text] [Related]
3. Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.
McClenaghan NH; Ball AJ; Flatt PR
Br J Pharmacol; 2000 May; 130(2):478-84. PubMed ID: 10807689
[TBL] [Abstract][Full Text] [Related]
4. Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure.
McClenaghan NH; Ball AJ; Flatt PR
Biochem Pharmacol; 2001 Mar; 61(5):527-36. PubMed ID: 11239495
[TBL] [Abstract][Full Text] [Related]
5. BPDZ 154 activates adenosine 5'-triphosphate-sensitive potassium channels: in vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism.
Cosgrove KE; Antoine MH; Lee AT; Barnes PD; de Tullio P; Clayton P; McCloy R; De Lonlay P; Nihoul-Fékété C; Robert JJ; Saudubray JM; Rahier J; Lindley KJ; Hussain K; Aynsley-Green A; Pirotte B; Lebrun P; Dunne MJ
J Clin Endocrinol Metab; 2002 Nov; 87(11):4860-8. PubMed ID: 12414839
[TBL] [Abstract][Full Text] [Related]
6. Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide.
Ball AJ; Flatt PR; McClenaghan NH
Eur J Pharmacol; 2000 Nov; 408(3):327-33. PubMed ID: 11090651
[TBL] [Abstract][Full Text] [Related]
7. Glucose activates both K(ATP) channel-dependent and K(ATP) channel-independent signaling pathways in human islets.
Straub SG; James RF; Dunne MJ; Sharp GW
Diabetes; 1998 May; 47(5):758-63. PubMed ID: 9588447
[TBL] [Abstract][Full Text] [Related]
8. Insulin-releasing action of the novel antidiabetic agent BTS 67 582.
McClenaghan NH; Flatt PR; Bailey CJ
Br J Pharmacol; 1998 Feb; 123(3):400-4. PubMed ID: 9504379
[TBL] [Abstract][Full Text] [Related]
9. Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line.
Sturgess NC; Kozlowski RZ; Carrington CA; Hales CN; Ashford ML
Br J Pharmacol; 1988 Sep; 95(1):83-94. PubMed ID: 3146398
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of insulin secretion in clonal BRIN-BD11 cells by the imidazoline derivatives KU14r and RX801080.
Ball AJ; Flatt PR; McClenaghan NH
Pharmacol Res; 2000 Dec; 42(6):575-9. PubMed ID: 11058411
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080.
Brown CA; Chan SL; Stillings MR; Smith SA; Morgan NG
Br J Pharmacol; 1993 Nov; 110(3):1017-22. PubMed ID: 7905338
[TBL] [Abstract][Full Text] [Related]
12. The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells.
Chan SL; Dunne MJ; Stillings MR; Morgan NG
Eur J Pharmacol; 1991 Oct; 204(1):41-8. PubMed ID: 1687123
[TBL] [Abstract][Full Text] [Related]
13. Glucose regulation of insulin secretion independent of the opening or closure of adenosine triphosphate-sensitive K+ channels in beta cells.
Sato Y; Anello M; Henquin JC
Endocrinology; 1999 May; 140(5):2252-7. PubMed ID: 10218978
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan.
Chan SL; Mourtada M; Morgan NG
Diabetes; 2001 Feb; 50(2):340-7. PubMed ID: 11272145
[TBL] [Abstract][Full Text] [Related]
15. Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion.
Mourtada M; Brown CA; Smith SA; Piercy V; Chan SL; Morgan NG
Br J Pharmacol; 1997 Jun; 121(4):799-805. PubMed ID: 9208151
[TBL] [Abstract][Full Text] [Related]
16. Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. II. Electrophysiological and fluorimetric studies.
Rustenbeck I; Dickel C; Grimmsmanns T
Biochem Pharmacol; 2001 Dec; 62(12):1695-703. PubMed ID: 11755123
[TBL] [Abstract][Full Text] [Related]
17. Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content.
Anello M; Gilon P; Henquin JC
Br J Pharmacol; 1999 Aug; 127(8):1883-91. PubMed ID: 10482920
[TBL] [Abstract][Full Text] [Related]
18. Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. I. Secretory and morphological studies.
Rustenbeck I; Winkler M; Jörns A
Biochem Pharmacol; 2001 Dec; 62(12):1685-94. PubMed ID: 11755122
[TBL] [Abstract][Full Text] [Related]
19. Clotrimazole and efaroxan stimulate insulin secretion by different mechanisms in rat pancreatic islets.
Chan SL; Pallett AL; Morgan NG
Naunyn Schmiedebergs Arch Pharmacol; 1997 Dec; 356(6):763-8. PubMed ID: 9453462
[TBL] [Abstract][Full Text] [Related]
20. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
Abdel-Zaher AO; Ahmed IT; El-Koussi AD
Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
